Measles virus (MV) is an infectious agent responsible for acute respiratory disease, which in rare instances is associated with lethal complications. However, in developing countries, measles is still one of the primary causes of infant mortality (7) . Nevertheless, the mechanisms of MV-induced immunopathology in general and those that lead to secondary complications in particular remain poorly understood.
A growing body of evidence suggests that subversion of transmembrane signaling by some viruses is involved in the pathogenesis of related diseases. However, the capacities of very few viruses to alter extracellular signal transduction have been examined so far. The exception is human immunodeficiency virus (HIV)-triggered increase of the intracellular concentrations of second messengers, such as Ca 2ϩ (47) and cyclic AMP (cAMP) (18, 37) , in human CD4
ϩ T cells and T-cell lines. It has been proposed that such a defective signal transduction may be relevant for the decreased capacity of HIVinfected lymphocytes to proliferate (42) .
One of the best-documented aspects of MV infection is acute immunosuppression characterized by the decreased capacity of T lymphocytes to proliferate under mitogenic challenge (29, 30) . This immunosuppression is also associated with a reduced frequency of mitogen-stimulated cells able to enter the S phase of the cell cycle (55) . The mechanisms responsible for such MV-dependent inhibition of T-lymphocyte proliferation remain to be elucidated. Apparently, these mechanisms do not involve the impairment of interleukin-2 (IL-2) transduction efficiency since neither IL-2 nor IL-2 receptor expression has been found to be modified in infected cells (55) . However, the possible alteration in transduction of other extracellular signals involved in the control of proliferation has not been assessed in MV-infected cells.
It has been suggested that neuropeptide somatostatin (SRIF) plays an autocrine role and/or a paracrine role in the regulation of a broad range of immune-cell functions, including proliferation. Particular SRIF effects on human T-cell proliferation are complex; they depend on neuropeptide concentration, the absence or presence of mitogens (i.e., SRIF can modulate mitogen-induced proliferation but cannot trigger it in the absence of mitogens), and on the time when SRIF is added with regard to the kinetics of T-cell activation (36, 39, 41) . For example, high (1 to 10 nM) SRIF14 concentrations (suggesting the involvement of low-affinity receptors) have a stimulatory effect on human T-lymphocyte proliferation (4) . However, SRIF14 inhibits phytohemagglutinin (PHA)-stimulated proliferation of human T lymphocytes at a concentration of 1 to 100 pM via a putative high-affinity receptor (41) .
Additional physiological roles of SRIF in the immune system include SRIF inhibition of some cytokine (e.g., gamma interferon and colony-stimulating factor) secretion by CD4 ϩ T cells and mononuclear leukocytes, respectively (8, 16) . SRIFdependent inhibition of inflammatory mediator production by basophils (13) and superoxide anion genesis by monocytes (35) has also previously been reported. Moreover, SRIF decreases secretion of certain immunoglobins (immunoglobulin A [IgA], IgE, and IgG4) by B lymphocytes (23, 48) .
The major biologically active form of the peptide (SRIF14) that underlies these physiological actions is produced, stored, and probably secreted by subpopulations of T and B cells (1) and macrophages (53) . Moreover, SRIF-specific binding has previously been detected on the surfaces of human T lymphocytes and T-cell lines (8, 17, 50, 51) , B cells (50, 51) , mast cells (44) , and monocytes (6) .
Furthermore, the inhibitory actions of SRIF on adenylyl cyclase in normal (38) and transformed (21) human lymphocytes have also previously been documented. Moreover, cAMP is currently well recognized as a second messenger that mediates the inhibition of T-lymphocyte proliferation (52) .
Very recently, it has been reported that SRIF inhibits mitogen-induced proliferative responses of both CD4 ϩ and CD8 ϩ T lymphocytes from HIV-infected subjects (32) . Moreover, a decrease in cAMP production upon adenylyl cyclase inhibition restores the impaired capacity of CD4 ϩ lymphocytes originating from HIV-seropositive subjects to proliferate under mitogenic challenge (19) . However, modulation of SRIF transduction in T cells subsequent to infection by other viruses able to inhibit lymphocyte proliferation has not yet been examined.
In the present work, we hypothesized that SRIF-dependent modulation of proliferation plays a role in MV-associated impairment of lymphocyte proliferation and asked whether MV might alter the SRIF actions on human T cells at the transduction level.
To assess that possibility, we studied the properties of SRIF binding sites and their coupling to adenylyl cyclase in MVinfected, mitogen-activated Jurkat T cells and human peripheral blood mononuclear cells (PBMC). A comparison of receptor numbers (determined by saturation of radiolabeled-SRIF binding at equilibrium) between control and infected cells showed that MV altered SRIF14 transduction by decreasing the receptor number. In addition, MV infection potentiated SRIF-dependent inhibition of adenylyl cyclase via remaining receptors. This altered SRIF signal transduction appears to be associated with the impaired proliferative capacity of MVinfected cells. Cell culture. Jurkat cells (clone J77.6.8) were grown in RPMI 1640 medium (Gibco, Cergy-Pontoise, France) supplemented with 10% (vol/vol) heat-inactivated fetal calf serum (FCS) (Boehringer, Meylan, France), 2 mM L-glutamine, and 100 U of gentamicin per ml in a 5% CO 2 -humidified atmosphere at 37°C.
MATERIALS AND METHODS

Chemicals
PBMC were isolated from heparinized whole-blood samples of healthy donors (obtained through the Blood Transfusion Center of Gerland, Lyon, France) by density gradient centrifugation on Ficoll-Paque (Pharmacia Biotech, Orsay, France). The cellular suspension was enriched in T lymphocytes by passage through a nylon wool column as previously described (22) .
MV infection. For Jurkat cell infection, the cellular suspension was systematically divided into two batches; one was left uninfected (control), and the other was infected with MV (Hallé strain) at 0.5 PFU per cell as previously reported (34) . Cell viability was assessed by trypan blue exclusion at various time points after infection. A 48-h infection period was chosen since it offered the optimal ratio of cell infection to cell viability (55) (data not shown). Only batches in which viability exceeded 90% were used for further experiments. Aliquots of both control and infected groups were processed for flow cytometry analysis.
Human PBMC were infected as reported previously (55) . They were activated overnight with 2 g of PHA-L (Sigma) ml
Ϫ1
. Half of the activated cells was infected with 0.3 PFU of MV Hallé strain for 3 h; the other half was mock infected with the equivalent volume of Vero cell supernatant. Both halves were washed once and grown in complete RPMI 1640 medium-10% FCS supplemented with 2 g of PHA-L ml Ϫ1 for an additional 60 h. The efficiency of infection was checked as described below for Jurkat cells.
Flow cytometry analysis. MV infection was confirmed by both visualization of the MV envelope protein hemagglutinin (H) and monitoring downregulation of virus receptor (CD46) on the surfaces of Jurkat cells (34) Cells from control and infected groups were sedimented by quick centrifugation (1,000 ϫ g, 5 min, 25°C) and washed three times in cell culture medium. After the last wash, cell pellets were resuspended in a small volume of 50 mM Tris-HCl buffer (pH 7.4), transferred to a glass-glass homogenizer, and broken by 20 hand strokes. Homogenates were centrifuged for 3 min at 1,800 ϫ g (4°C); pellets were discarded, and supernatants were recentrifuged for 15 min at 28,000 ϫ g (4°C). The resulting pellets were resuspended in an incubation buffer consisting of 50 mM Tris-HCl buffer (pH 7.4) supplemented with 5 mM MgCl 2 , 0.2% (wt/vol) bovine serum albumin, and 0.05% (wt/vol) bacitracin. Aliquots of these semipurified membrane preparations were frozen and kept at Ϫ80°C until used.
The Adenylyl cyclase assay. Semipurified membrane fractions for the adenylyl cyclase assay were prepared as described above for binding assays except that cells were homogenized by 10 hand strokes in 1 mM Tris-maleate buffer (pH 7.2) supplemented with 10 mM EGTA and 1% (wt/vol) sucrose and frozen in the same buffer containing 10 mM EGTA and 10% (wt/vol) sucrose.
Adenylyl cyclase activities were measured by the conversion of [␣- Cell proliferation assay. Prior to cell proliferation assay, both Jurkat cells and PBMC were mitogen stimulated. Jurkat cells were incubated for 24 h in the presence of a combination of 1 g of PHA-L ml Ϫ1 and 16 nM phorbol ester (Sigma). Indeed, it has been previously reported that mitogen stimulation of Jurkat cells displays a two-stimulus requirement (54) . PBMC were activated with PHA-L (2 g ml Ϫ1 ) for 72 h; under such experimental conditions, this lectin has been previously reported to induce T-lymphocyte proliferation specifically (55 (31) . Differences between groups of control and infected cells were statistically assessed by oneway analysis of variance and considered significant at a P value of Ͻ0.05.
RESULTS
Setup of experimental conditions. In order to obtain a homogeneous population of MV-infected cells, Jurkat cells were systematically analyzed by flow cytofluorometry after infection. They were used for semipurified membrane fraction prepara-tion only if (i) the intensity of fluorescent labeling of the MV H protein on their surfaces was 100 times higher than that of MV H labeling of control cells (the latter labeling equaled background fluorescence, as determined with fluorescein-conjugated goat anti-mouse immunoglobulin) and (ii) their CD46 labeling was at least 10 times lower than the corresponding labeling of control cells (Fig. 1A) . These quantitative criteria were determined from previously reported data for MV-associated downregulation of the virus receptor (CD46) and concomitant expression of MV H protein on the surfaces of MVinfected Jurkat cells (34) . An arbitrary comparison with MVinfected Jurkat cells showed that PBMC were less readily infected by MV. Indeed, a longer infection period (60 versus 48 h for Jurkat cells) was needed in order to obtain MV H expression in about 75% of infected PBMC (compared with 80 to 90% of infected Jurkat cells). MV H expression in infected PBMC was only 10 times (compared with 100 times in infected Jurkat cells) higher than background labeling (compare MV H labeling to the background labeling in Fig. 1 ). In addition, the arbitrary (i.e., compared to the background labeling) fluorescence intensity of CD46 labeling in control PBMC was 3 orders of magnitude higher than that of background fluorescence (in comparison to a difference of 2 orders of magnitude for control Jurkat cells). After infection, downregulation of CD46 in PBMC occurred but surface CD46 labeling was decreased only 2-fold (Fig. 1B) in comparison to the 10-fold decrease measured in Jurkat cells (Fig. 1A) . Moreover, under our experimental conditions, 70% of MV-infected PBMC downregulated CD46 versus more than 80% of MV-infected Jurkat cells. Such relative heterogeneity of MV-infected PBMC (in comparison to MV-infected Jurkat cells) was expected because of previous reports that the kinetics of MV infection is asynchronous in a PBMC population (55) but not in a Jurkat cell population (34) .
In a previous report on Jurkat SRIF receptors, the binding studies were performed with whole cells (50) . However, such an experimental system does not allow the accurate correlation of receptor binding characteristics with the properties of receptor coupling to adenylyl cyclase (2) . In order to study such a correlation, we first set up the measurement of SRIF binding sites on semipurified cell membranes from control Jurkat cells.
[ 125 I]Tyr 1 -SRIF14 bound specifically to semipurified membrane preparations of control Jurkat cells. A steady-state equilibrium at 25°C was reached after 60 min of incubation and maintained for up to 120 min ( Fig. 2A) . Specific binding represented 50 to 55% of total binding; it was linear for protein concentrations of up to 100 g per assay (Fig. 2B) . ments was 43 Ϯ 6 fmol mg of protein Ϫ1 , of which 56% Ϯ 9% represented the binding site characterized by K d1 and 39% Ϯ 7% corresponded to the low-affinity binding site (Fig. 3A) .
In (Fig. 4A) .
However, in MV-infected Jurkat cells, SRIF14 inhibition of [ 125 I]Tyr 1 -SRIF14-specific binding was monophasic, did not rise above more than 2 orders of magnitude, and yielded a unique K i of 127 Ϯ 19 pM (Fig. 4A) .
In PHA-activated control PBMC, competition experiments showed the presence of two [
125 I]Tyr 1 -SRIF14-specific binding sites (K i1 ϭ 111 Ϯ 31 pM and K i2 ϭ 17 Ϯ 2 nM, [mean Ϯ SEM]; n ϭ 2; Fig. 4B ). In contrast, membrane preparations obtained from MV-infected, PHA-activated PBMC contained a single binding site (K i1 ϭ 48 Ϯ 15 pM [mean Ϯ SEM]; n ϭ 2; Fig. 4B ). Altogether, these data strongly indicated that in contrast to controls, in both MV-infected Jurkat cells and MV-infected PBMC, SRIF14 interacted with a single population of binding sites.
MV infection modulates SRIF receptor coupling to adenylyl cyclase. In control Jurkat cells, SRIF14 inhibited basal adenylyl cyclase activity in a monophasic manner with an IC 50 of 22 Ϯ 4 pM, thus suggesting that a single class of SRIF14 binding sites interacts with this enzyme (Fig. 5) . However, SRIF14-dependent adenylyl cyclase inhibition was modest (12% Ϯ 1%); it was achieved at a 1 nM concentration and remained unchanged at an SRIF14 concentration of up to 1 M (Fig. 5) .
In MV-infected Jurkat cells, a pronounced enhancement of the maximal inhibitory effect of SRIF14 was observed; at a 1 M peptide concentration, it was 25% Ϯ 3% (Fig. 5) . Although the maximal inhibition of adenylyl cyclase measured in MV-infected Jurkat cells was modest, it was of the same order of magnitude as those reported for SRIF inhibition in other tissues (10) . However, the efficiency of SRIF14 to inhibit adenylyl cyclase (IC 50 ϭ 83 Ϯ 10 pM) was not significantly different from that determined in control cells (IC 50 ϭ 22 Ϯ 4 pM) (Fig. 5) . These data indicated that although the same SRIF14 binding site mediated adenylyl cyclase inhibition in both control and MV-infected cells, this inhibition was more efficient in MV-infected cells.
To assess whether MV infection generally affects adenylyl cyclase activity, we tested forskolin-dependent activation and compared control and MV-infected Jurkat cells. Forskolin is a plant alkaloid that directly targets the enzyme catalytic activity; it has been used to estimate the functional capacity of adenylyl cyclase to be activated (20) .
In control Jurkat cells, forskolin (10 M) increased adenylyl cyclase activity three-to fourfold from basal values ( Table 1) . Such an increase was limited, compared to the 10-to 12-fold forskolin activation of rat brain (striatum) adenylyl cyclase activity taken as the positive control ( Table 1 ). The data obtained for the positive control were in perfect agreement with those reported in the literature (3, 49) . Consistently, it was reported more than 15 years ago that in numerous other tissues (e.g., pancreas, small intestine, stomach, lung, and testes), forskolin (100 M) triggered only a 2-to 4-fold increase of adenylyl cyclase activity (49) in contrast to a 10-to 15-fold increase in the brain.
MV infection significantly decreased the capacity of adenylyl cyclase to be activated by forskolin. In MV-infected Jurkat cells, basal activity was 2.2 Ϯ 0.7 pmol mg Ϫ1 min Ϫ1 , whereas it was 3.3 Ϯ 0.1 pmol mg Ϫ1 min Ϫ1 upon forskolin (10 M) stimulation ( Table 1 ). The absence of activation could not be attributed to an insufficient forskolin concentration since no significant increase of adenylyl cyclase activity was obtained with 100 M forskolin (Table 1) . Moreover, vasoactive intestinal peptide (VIP), a potent activator of adenylyl cyclase in T lymphocytes (38) , was unable to increase the enzyme activity in MV-infected cells (Table 1 ). In contrast, in control cells, depending on the concentration used, VIP was 5 to 15 times more potent than was forskolin (Table 1) .
MV infection impairs the capacity of SRIF to modulate the proliferation of Jurkat cells and human T lymphocytes. In the absence of mitogens, SRIF14 was not able to induce increased [methyl-
3 H]thymidine incorporation in either type of control cells, thus excluding any mitogenic effect of SRIF per se. This result is in accord with previously published observations (36, 41) . In contrast, in the absence of MV infection, SRIF14 triggered an increase in [methyl-
3 H]thymidine uptake at concentrations of between 1 pM and 1 M in both mitogen-activated Jurkat cells (Fig. 6A ) and human PBMC (Fig. 6B) .
MV infection significantly decreased [methyl-3 H]thymidine uptake in the absence of SRIF14 (from 161,515 Ϯ 1,582 to 88,817 Ϯ 636 and from 121,393 Ϯ 2,149 to 42,100 Ϯ 505 cpm for mitogen-activated Jurkat and human PBMC, respectively). The for Jurkat cells and PBMC, respectively. Under the experimental conditions in which at least three-fourths of both cell populations were infected ( Fig. 1 ) (see Materials and Methods), MV-related inhibition of mitogen-stimulated proliferation is about 50 and 40% for Jurkat cells and PBMC, respectively (Fig. 6 ). These data validate the experimental conditions chosen for cell activation and infection of PBMC since they are in perfect agreement with those previously reported (55) .
However, after MV infection, SRIF14 was unable to trigger an increase of proliferation in either cell type studied (Fig. 6) . Therefore, although noninfected cells constitute one-fourth of the total cell population and are able to increase their mitogendriven proliferative response in the presence of SRIF, such an SRIF-dependent increase of proliferation is invisible since the great majority (three-fourths) of cells display an MV-associated, inhibited proliferative response. Indeed, using an elegant experimental design, Yanagi and coworkers reported that both noninfected and MV-infected cells (taking as a criterion of infection the expression of viral antigens on the surfaces of cells) proliferated in response to mitogens, but the response of MV-infected cells was partially inhibited (55) . Altogether, our data strongly suggest that SRIF is able to increase proliferative responses to mitogens only in control cells, not in MV-infected cells.
DISCUSSION
The most important finding of the present study is that in human T cells, MV modulates SRIF signal transduction at both receptor and receptor transmembrane coupling levels. The experimental approach used was validated by comparing the equilibrium binding characteristics of SRIF receptors determined in our study to those reported previously. The binding parameters that we obtained for the sites of high (38 Ϯ 5 pM) and low (18 Ϯ 1 nM) affinities are in perfect agreement with those described for whole Jurkat cells (50) . For human PBMC, the affinity of low-affinity binding sites (K i2 ϭ 17 Ϯ 2 nM) is identical to that previously reported in the only other published study (17) . However, they could not assess the possible existence of the high-affinity binding sites that we identified in the present study since the SRIF14 concentration range they used to perform 125 I-SRIF14 binding inhibition was limited to the high peptide concentration (0.1 M to 0.1 mM) (17) .
Our data show that MV infection triggers a two-to threefold decrease of the total SRIF binding site number in human T cells. Similarly, it has previously been reported that in canine distemper virus-infected cells, the number of ␤-adrenergic receptors (which belong to the same Gs protein-coupled receptor superfamily as do SRIF receptors) is reduced to half the number in noninfected cells (24) . Rabies virus infection has previously been shown to modulate brain IL-1 receptors (15) .
Furthermore, MV infection triggers a disappearance of the low-affinity SRIF binding site in both Jurkat cells and PHAactivated human PBMC. It is not yet clear whether the highaffinity binding site in control cells and the sole persisting binding site in MV-infected cells are the same molecular entity or two distinct molecules with slightly different affinities. Indeed, the affinities of these two binding sites differ by only about 1 order of magnitude, which can refer to not only two different receptors but also to one receptor that exists in two affinity states. These points will certainly be clarified in the near future when specific antibodies recognizing recently cloned SRIF receptors become available.
Some important fundamental questions are raised by the present study. Why do human T cells express two (or more) different SRIF receptors? The physiological significance of the multiplicity of SRIF receptors in previously examined tissues, such as the brain, pancreas, gut, and kidney, remains unknown (5, 25, 43) . In particular, it is not clear whether different receptors serve different biological actions of SRIF in these tissues since a specific biological function could not be attributed to any of the cloned SRIF receptor isotypes (5, 43) . However, selective modulation of certain receptors in some pathological situations has previously been reported. For example, in brains of patients suffering from Alzheimer's disease, SRIF receptors defined pharmacologically as high-affinity binding sites sensitive to SMS 201-995 were selectively downregulated (26) . Reminiscent of this is the fact that MV triggered selective downregulation of one specific (i.e., low-affinity) SRIF receptor in T cells. This suggests strongly that although they overlap in tissue expression, distinct SRIF receptors are not functionally redundant.
In addition to the observed effects of MV infection on SRIF receptors, we were able to show profound, MV-dependent modifications of adenylyl cyclase coupling to competent receptors. Our data point to specific potentiation of SRIF14-dependent inhibition of adenylyl cyclase in MV-infected Jurkat cells. Moreover, MV effects on adenylyl cyclase activity were not limited to receptors that mediate enzyme inhibition, such as SRIF receptors. Indeed, MV infection severely abolished the capacity of adenylyl cyclase to be stimulated via Gs proteincoupled VIP receptors. Furthermore, direct stimulation of adenylyl cyclase by forskolin was also lost in infected cells. These data are in perfect agreement with those previously reported for the loss of adenylyl cyclase activation by a ␤-adrenergic agonist (DL-isoproterenol) after an MV-like paramyxovirus (SSPE virus) infection (14) . The incapacity of adenylyl cyclase to be activated in MV-infected cells is thus independent of the mechanism of its activation. Indeed, in contrast to forskolin, which directly increases the catalytic activity of adenylyl cyclase (20) , VIP activation (45) and ␤-adrenergic activation (27) involve Gs protein coupling.
In light of the pathophysiological alterations associated with MV infection, the observed SRIF-dependent inhibition of adenylyl cyclase activity may be a compensatory consequence of the demonstrated SRIF receptor downregulation. Therefore, MV-dependent overall inhibition of adenylyl cyclase activity (by reinforcement of negative SRIF-like regulation and suppression of positive VIP-like regulation) may be an adaptative clue elaborated by the virus during coevolution with its cellular host. Concordant with such a presumption is the reported inhibition of MV replication by increasing cAMP concentrations (46) .
For infected T cells, prominent enhancement of adenylyl cyclase inhibition via remaining SRIF receptors would result in increased proliferation since cAMP has antiproliferative actions in these cells (52) . Such an expected release of cAMPdependent inhibition of proliferation may be relevant to the fact that only activated (i.e., proliferating) lymphocytes can support MV replication (55) . However, under the experimental conditions chosen, putative enhancement of the infectedcell proliferative capacity by SRIF could not be shown. An interesting hypothesis to explain the observed impairment of SRIF-dependent increase of proliferation in infected cells is that MV infection either switches on or reinforces the positive coupling of SRIF receptors to phosphotyrosine phosphatase. Indeed, positive coupling of SRIF receptors to PTP 1D-like phosphotyrosine phosphatase relevant to the inhibition of proliferation has been recently reported (11) .
Otherwise, the absence of an SRIF-dependent increase of mitogen-induced proliferation that we report here for MV-infected cells may be related to a specific disappearance of low-affinity SRIF receptor (hypothetically associated with proliferative actions of SRIF [17, 40, 41] ) after MV infection. However, the hypothesis that postulated the mediation of SRIF proliferative and antiproliferative effects via low-and high-affinity receptors, respectively, was not verified under our experimental conditions. Indeed, although SRIF is not a mitogen per se in control cells, it triggered an increase of mitogen-induced proliferation at all the concentrations (1 pM to 1 M) tested. Alternatively, the incapacity of infected cells to respond to SRIF by increasing mitogen-driven proliferation may be related to additional coupling of the remaining receptors to antiproliferative effectors, such as phosphotyrosine phosphatase (see above). Such a decreased capacity to proliferate may be relevant to the antiviral defense mechanism elaborated by host cells in order to limit their own proliferation and therefore prevent MV spread.
In conclusion, the data presented here show severe impairment of SRIF signal transduction in MV-infected human T lymphocytes and a T-cell line. Such impairment is apparently related to the incapacity of MV-infected cells to increase proliferative responses to mitogens in the presence of SRIF. Our results also provide further evidence for the existence of as-yet poorly understood mechanisms associated with virus-provoked dysfunction at the transduction level. Moreover, our findings open new research avenues for the treatment of MV infection. For example, pharmacological manipulation of proliferationassociated adenylyl cyclase activity via blockage of its inhibition by SRIF-selective antagonists that specifically target infected T cells may turn out to be a useful therapeutic tool. Indeed, similar pharmacological attempts have proven to be helpful in repairing the capacity of lymphocytes from HIV-seropositive subjects to proliferate upon mitogenic challenge (19) .
